Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia

Autor(es)

Siviero-Miachon, Adriana Aparecida ; Spinola-Castro, Angela Maria ; de Martino Lee, Maria Lucia ; Calixto, Antonio Ramos ; Geloneze, Bruno ; Lazaretti-Castro, Marise ; Guerra-Junior, Gil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF BONE AND MINERAL METABOLISM; v. 35, n. 1, p. 73-82, JAN 2017.
• Citações Web of Science: 2

Resumo

Bone mass acquisition may be compromised in survivors of childhood acute lymphocytic leukemia due to various factors, including adiposity. Fat accumulation can affect bone through the direct effect of adipokines or indirectly through the state of chronic inflammation. The aim of this study was to evaluate the effect of body composition and adipokines on bone mass in survivors of acute lymphocytic leukemia. This was a cross-sectional study of 56 survivors aged between 15 and 24 years, 44.6 % of whom received cranial radiotherapy (18-24 Gy), assessed according to body fat, lean mass, and bone mineral density (dual energy X-ray absorptiometry), computed tomography scan-derived abdominal adipose tissue, and adipokines by a multiple regression analysis. Both lumbar spine L-1-L-4 (trabecular bone) and total body (cortical bone) bone mineral density were positively correlated with visfatin (p < 0.050). Lean mass index was positively correlated, while waist-to-height ratio was negatively correlated with cortical bone (p < 0.010). Low bone mineral density for chronological age was detected in 5.4 % of patients in total body, and 8.9 % at the lumbar spine. In survivors of acute lymphocytic leukemia, visfatin may play an important role in the complex relationship between body composition and bone. At present, visfatin may represent a model for further study of bone metabolism, and could possibly explain the unknown mechanisms linking bone metabolism and cancer. (AU)

• Processo FAPESP: 06/06162-9 - Risco cardiovascular em adolescentes e adultos jovens tratados por leucemia linfocítica
• Beneficiário: Gil Guerra Júnior
• Modalidade de apoio: Auxílio à Pesquisa - Regular